<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02765711</url>
  </required_header>
  <id_info>
    <org_study_id>2016-ZX07</org_study_id>
    <secondary_id>ESR-15-11199</secondary_id>
    <nct_id>NCT02765711</nct_id>
  </id_info>
  <brief_title>Ticagrelor in Fuwai Hospital</brief_title>
  <acronym>TIFU</acronym>
  <official_title>TIFU: A Non-Interventional, Descriptive Cohort Study to Describe the Use of Ticagrelor in Patients With Acute Coronary Syndrome (TIFU: Ticagrelor in Fuwai Hospital)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <brief_summary>
    <textblock>
      This is a single-arm non-interventional cohort study. This study is to describe the
      contemporary use of ticagrelor in a &quot;real-world&quot; setting, to reflect its acceptance and
      patients' compliance, and to observe its one-year safety in patients with acute coronary
      syndrome in Fuwai Hospital.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with switching between clopidogrel and ticagrelor</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with switching between clopidogrel and ticagrelor without a reloading dose</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with discontinuation of P2Y12 receptor antagonist</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with ticagrelor combined with other anticoagulants</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Mortality, Myocardial Infarction(MI), Ischemic Stoke</measure>
    <time_frame>12 months</time_frame>
    <description>composite incidence
Myocardial infarction is defined and subclassified in accordance with ACC/AHA/ESC third universal definition of myocardial infarction
Ischemic stroke: an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction, defined by at least one of the following:
Pathological, imaging, or other objective evidence of acute, focal cerebral, spinal, or retinal ischemic injury in a defined vascular distribution
Symptoms of acute cerebral, spinal, or retinal ischemic injury persisting ≧24 h, with other etiologies excluded
Hemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding event will be recorded (defined in accordance with PLATO definition)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>the use of ticagrelor in hospital</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This study will include more than 1200 ACS patients using ticagrelor in Fuwai hospital from
        May 2016 to May 2017.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≧18 years

          2. Established diagnosis of acute coronary syndrome

          3. The use of ticagrelor in hospital

          4. agree to join this clinical trial and sign informed consent

        Exclusion Criteria:

          1. Life-expectancy &lt;1 year

          2. Dialysis required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongbing Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongbing Yan, MD</last_name>
    <phone>+8610-88322287</phone>
    <email>yanhongbingsuifang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Liu, MD</last_name>
    <phone>+8610-88322287</phone>
    <email>tifuliu@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongbing Yan, MD</last_name>
      <phone>+8610-88322287</phone>
      <email>yanhongbingsuifang@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Juan Liu, MD</last_name>
      <phone>+8610-88322287</phone>
      <email>tifuliu@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>July 31, 2016</last_update_submitted>
  <last_update_submitted_qc>July 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Hongbing Yan</investigator_full_name>
    <investigator_title>The deputy director of Center of Coronary Heart Disease and Center of Chest Pain</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

